GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinoma.
GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinoma.
复制标题
DOI：
10.1016/j.humpath.2014.05.011
复制
发表时间：
2014-09
期刊：
影响因子：
3.3
通讯作者：
Serrero, Ginette
中科院分区：
文献类型：
--
作者：
Edelman, Martin J.;Feliciano, Josephine;Yue, Binbin;Bejarano, Pablo;Ioffe, Olga;Reisman, David;Hawkins, Douglas;Gai, Qiwei;Hicks, David;Serrero, Ginette
关键词：
GP88（颗粒体蛋白前体）是一种与肿瘤发生和耐药性有关的生长和生存因子。既往研究表明，GP88在乳腺癌组织中表达，与生存率呈负相关。本研究评估了局限性/局部晚期肺癌中的 GP88 组织表达以及晚期疾病中的 GP88 血清水平。通过免疫组织化学方法测定非小细胞癌 (NSCLC) 患者肿瘤组织中的 GP88 表达，其中 85 名患者为局限性（I-II 期）患者，40 名患者为局部晚期疾病（IIIa 期），并与临床结果相关。将通过酶免疫测定 (EIA) 定量的 IIIb/IV 期患者的血清 GP88 水平与慢性阻塞性肺疾病 (COPD) 患者和健康个体的 GP88 水平进行比较。与正常肺癌或小细胞肺癌相比，GP88 在 >80% 的腺癌和鳞状细胞癌中表达。 GP88 表达（GP88 免疫组织化学评分 3+ 与 <3+）与局部切除 NSCLC 患者的生存率呈显着负相关，DFS 的风险比 (HR)=2.28 (p=0.0076)，OS 的 HR=2.17 (p=0.014)。放化疗后，IIIa 期 GP88 评分 3+ 与 <3+ 相比，无进展生存率显着下降（HR=2.9，p=0.022）。此外，与对照受试者相比，IIIb/IV 期 NSCLC 中的血清 GP88 显着升高（49.9ng/ml vs. 28.4ng/ml，p<0.0001）。这是第一项证明 GP88 组织和血清表达作为局部和晚期疾病的预后生物标志物的研究。未来的研究将确定监测 GP88 的效用以及 GP88 表达作为抗 GP88 治疗的预测标记的潜力。
GP88 (progranulin) is a growth and survival factor implicated in tumorigenesis and drug resistance. Previous studies showed that GP88 was expressed in breast cancer tissue in inverse correlation with survival. This study evaluates GP88 tissue expression in localized/locally advanced lung cancer and GP88 serum levels in advanced disease. GP88 expression was determined by immunohistochemistry in tumor tissue from non-small cell carcinoma (NSCLC) patients, 85 with localized (Stage I-II) and 40 with locally advanced disease (Stage IIIa) and correlated with clinical outcome. Serum GP88 levels from Stage IIIb/IV patients, quantified by Enzyme Immunoassay (EIA) were compared to GP88 levels from patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy individuals. GP88 was expressed in >80% adenocarcinoma and squamous cell carcinoma in contrast to normal lung or small cell lung cancer. There was a statistically significant inverse association of GP88 expression (GP88 Immunohistochemistry score 3+ vs. <3+) with survival for patients with localized resected NSCLC with Hazard Ratio (HR)=2.28 (p=0.0076) for DFS and HR=2.17 (p=0.014) for OS. A statistically significant decrease in progression-free survival (HR=2.9, p=0.022) for GP88 scores of 3+ vs. <3+ was observed for Stage IIIa after chemoradiotherapy. In addition, serum GP88 was significantly elevated in Stage IIIb/IV NSCLC compared to control subjects (49.9ng/ml vs. 28.4ng/ml, p<0.0001). This is the first study demonstrating GP88 tissue and serum expression as a prognostic biomarker in localized and advanced disease. Future research will determine utility of monitoring GP88 and the potential of GP88 expression as a predictive marker for anti-GP88 therapeutics.
登录
查看更多内容
影响因子：
82.9
作者：
He, ZH;Ong, CHP;Bateman, A
通讯作者：
Bateman, A
影响因子：
8
作者：
Tolkatchev, Dmitri;Malik, Suneil;Ni, Feng
通讯作者：
Ni, Feng
DOI：
10.1186/bcr3111
发表时间：
2012-02-08
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Serrero G;Hawkins DM;Yue B;Ioffe O;Bejarano P;Phillips JT;Head JF;Elliott RL;Tkaczuk KR;Godwin AK;Weaver J;Kim WE
通讯作者：
Kim WE
影响因子：
11.5
作者：
Kim, Wes E.;Serrero, Ginette
通讯作者：
Serrero, Ginette
影响因子：
4.7
作者：
Tangkeangsirisin, W;Serrero, G
通讯作者：
Serrero, G